Cargando…

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy

Myeloid-derived suppressor cells (MDSC) are a subset of immature myeloid cells with suppressive activity well described in the context of cancer. They inhibit anti-tumour immunity, promote metastasis formation and can lead to immune therapy resistance. In a retrospective study, blood probes of 46 ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomela, Katarzyna, Pietrzak, Bernadeta, Galus, Łukasz, Mackiewicz, Jacek, Schmidt, Marcin, Mackiewicz, Andrzej Adam, Kaczmarek, Mariusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000540/
https://www.ncbi.nlm.nih.gov/pubmed/36899926
http://dx.doi.org/10.3390/cells12050789
_version_ 1784903903181012992
author Tomela, Katarzyna
Pietrzak, Bernadeta
Galus, Łukasz
Mackiewicz, Jacek
Schmidt, Marcin
Mackiewicz, Andrzej Adam
Kaczmarek, Mariusz
author_facet Tomela, Katarzyna
Pietrzak, Bernadeta
Galus, Łukasz
Mackiewicz, Jacek
Schmidt, Marcin
Mackiewicz, Andrzej Adam
Kaczmarek, Mariusz
author_sort Tomela, Katarzyna
collection PubMed
description Myeloid-derived suppressor cells (MDSC) are a subset of immature myeloid cells with suppressive activity well described in the context of cancer. They inhibit anti-tumour immunity, promote metastasis formation and can lead to immune therapy resistance. In a retrospective study, blood probes of 46 advanced melanoma patients were analysed before the first administration of anti-PD-1 immunotherapy and in the third month of treatment for MDSC, immature monocytic (ImMC), monocytic MDSC (MoMDSC) and granulocytic MDSC (GrMDSC) by multi-channel flow cytometry. Cell frequencies were correlated with response to immunotherapy, progression-free survival (PFS) and lactate dehydrogenase (LDH) serum level. Responders to anti-PD-1 therapy had higher MoMDSC levels (4.1 ± 1.2%) compared to non-responders (3.0 ± 1.2%) (p = 0.0333) before the first administration of anti-PD-1. No significant changes in MDSCs frequencies were observed in the groups of patients before and in the third month of therapy. The cut-off values of MDSCs, MoMDSCs, GrMDSCs and ImMCs for favourable 2- and 3-year PFS were established. Elevated LDH level is a negative prognostic factor of response to the treatment and is related to an elevated ratio of GrMDSCs and ImMCs level compared to patients’ LDH level below the cut-off. Our data may provide a new perspective for more careful consideration of MDSCs, and specially MoMDSCs, as a tool for monitoring the immune status of melanoma patients. Changes in MDSC levels may have a potential prognostic value, however a correlation with other parameters must be established.
format Online
Article
Text
id pubmed-10000540
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100005402023-03-11 Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy Tomela, Katarzyna Pietrzak, Bernadeta Galus, Łukasz Mackiewicz, Jacek Schmidt, Marcin Mackiewicz, Andrzej Adam Kaczmarek, Mariusz Cells Article Myeloid-derived suppressor cells (MDSC) are a subset of immature myeloid cells with suppressive activity well described in the context of cancer. They inhibit anti-tumour immunity, promote metastasis formation and can lead to immune therapy resistance. In a retrospective study, blood probes of 46 advanced melanoma patients were analysed before the first administration of anti-PD-1 immunotherapy and in the third month of treatment for MDSC, immature monocytic (ImMC), monocytic MDSC (MoMDSC) and granulocytic MDSC (GrMDSC) by multi-channel flow cytometry. Cell frequencies were correlated with response to immunotherapy, progression-free survival (PFS) and lactate dehydrogenase (LDH) serum level. Responders to anti-PD-1 therapy had higher MoMDSC levels (4.1 ± 1.2%) compared to non-responders (3.0 ± 1.2%) (p = 0.0333) before the first administration of anti-PD-1. No significant changes in MDSCs frequencies were observed in the groups of patients before and in the third month of therapy. The cut-off values of MDSCs, MoMDSCs, GrMDSCs and ImMCs for favourable 2- and 3-year PFS were established. Elevated LDH level is a negative prognostic factor of response to the treatment and is related to an elevated ratio of GrMDSCs and ImMCs level compared to patients’ LDH level below the cut-off. Our data may provide a new perspective for more careful consideration of MDSCs, and specially MoMDSCs, as a tool for monitoring the immune status of melanoma patients. Changes in MDSC levels may have a potential prognostic value, however a correlation with other parameters must be established. MDPI 2023-03-02 /pmc/articles/PMC10000540/ /pubmed/36899926 http://dx.doi.org/10.3390/cells12050789 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tomela, Katarzyna
Pietrzak, Bernadeta
Galus, Łukasz
Mackiewicz, Jacek
Schmidt, Marcin
Mackiewicz, Andrzej Adam
Kaczmarek, Mariusz
Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
title Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
title_full Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
title_fullStr Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
title_full_unstemmed Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
title_short Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
title_sort myeloid-derived suppressor cells (mdsc) in melanoma patients treated with anti-pd-1 immunotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000540/
https://www.ncbi.nlm.nih.gov/pubmed/36899926
http://dx.doi.org/10.3390/cells12050789
work_keys_str_mv AT tomelakatarzyna myeloidderivedsuppressorcellsmdscinmelanomapatientstreatedwithantipd1immunotherapy
AT pietrzakbernadeta myeloidderivedsuppressorcellsmdscinmelanomapatientstreatedwithantipd1immunotherapy
AT galusłukasz myeloidderivedsuppressorcellsmdscinmelanomapatientstreatedwithantipd1immunotherapy
AT mackiewiczjacek myeloidderivedsuppressorcellsmdscinmelanomapatientstreatedwithantipd1immunotherapy
AT schmidtmarcin myeloidderivedsuppressorcellsmdscinmelanomapatientstreatedwithantipd1immunotherapy
AT mackiewiczandrzejadam myeloidderivedsuppressorcellsmdscinmelanomapatientstreatedwithantipd1immunotherapy
AT kaczmarekmariusz myeloidderivedsuppressorcellsmdscinmelanomapatientstreatedwithantipd1immunotherapy